End-tidal carbon dioxide monitoring using a naso-buccal sensor is not appropriate to monitor capnia during non-invasive ventilation.

BACKGROUND: In acute respiratory failure, arterial blood gas analysis (ABG) is used to diagnose hypercapnia. Once non-invasive ventilation (NIV) is initiated, ABG should at least be repeated within 1 h to assess PaCO2 response to treatment in order to help detect NIV failure. The main aim of this study was to assess whether measuring end-tidal CO2 (EtCO2) with a dedicated naso-buccal sensor during NIV could predict PaCO2 variation and/or PaCO2 absolute values. The additional aim was to assess whether active or passive prolonged expiratory maneuvers could improve the agreement between expiratory CO2 and PaCO2. METHODS: This is a prospective study in adult patients suffering from acute hypercapnic respiratory failure (PaCO2 ≥ 45 mmHg) treated with NIV. EtCO2 and expiratory CO2 values during active and passive expiratory maneuvers were measured using a dedicated naso-buccal sensor and compared to concomitant PaCO2 values. The agreement between two consecutive values of EtCO2 (delta EtCO2) and two consecutive values of PaCO2 (delta PaCO2) and between PaCO2 and concomitant expiratory CO2 values was assessed using the Bland and Altman method adjusted for the effects of repeated measurements. RESULTS: Fifty-four datasets from a population of 11 patients (8 COPD and 3 non-COPD patients), were included in the analysis. PaCO2 values ranged from 39 to 80 mmHg, and EtCO2 from 12 to 68 mmHg. In the observed agreement between delta EtCO2 and deltaPaCO2, bias was -0.3 mmHg, and limits of agreement were -17.8 and 17.2 mmHg. In agreement between PaCO2 and EtCO2, bias was 14.7 mmHg, and limits of agreement were -6.6 and 36.1 mmHg. Adding active and passive expiration maneuvers did not improve PaCO2 prediction. CONCLUSIONS: During NIV delivered for acute hypercapnic respiratory failure, measuring EtCO2 using a dedicating naso-buccal sensor was inaccurate to predict both PaCO2 and PaCO2 variations over time. Active and passive expiration maneuvers did not improve PaCO2 prediction. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01489150.

Developing finished product stocking in a ventilation equipment company

Opinnäytetyön tavoitteena oli analysoida ja kehittää lopputuotteiden varastointia Halton Oy:ssä. Työ toteutettiin, koska yrityksen laajasta tuotevalikoimasta monia nimikkeitä varastoidaan tällä hetkellä ja ne sitovat runsaasti pääomaa varastoon. Lisäksi yrityksellä on vain rajallinen varastointitila käytettävissä ja sitä haluttiin hyödyntää optimaalisesti. Työssä suunniteltiin yritykselle varastoitavien tuotenimikkeiden hallintaprosessi ja lisäksi tutkittiin kuinka yritys voisi tarjota tuotteitaan nopeammin tärkeimmille ulkomaan markkina-alueille. Työn alussa huomio kohdistui myynniltään vähemmän merkittäviin varastonimikkeisiin, joita analysoitiin suunniteltujen kriteerien avulla. Tarkoituksena oli selvittää, mitkä varastonimikkeistä voitaisiin siirtää tilausohjautuviksi. Tärkeimpinä analysointikriteereinä käytettiin nimikkeiden alhaista myyntimäärää, lyhyttä tuotannonläpimenoaikaa sekä varastoitavien nimikkeiden lukumäärää tuoteryhmässä. Työssä huomioitiin kuitenkin myös muita mahdollisia syitä varastointiin. Lisäksi tehtiin havaintoja tilausohjautuvista nimikkeistä, jotka saattaisivat tarvita varastointia. Suunniteltuun hallintaprosessiin sisältyi kriteerien lisäksi myös varastotasojen määrittäminen yrityksen nykyisen varastomallin pohjalta. Työssä tutkittiin kuitenkin myös mahdollisia tulevaisuuden varastomalleja, joiden tarkoituksena olisi parantaa asiakaspalvelua ulkomailla. Tutkimus keskittyi pääasiassa nimikkeiden kysyntöjen analysointiin eri varastomallien myyntialueilla.

Impact of a Dedicated Noninvasive Ventilation Team on Intubation and Mortality Rates in Severe COPD Exacerbations.

BACKGROUND: Compared with usual care, noninvasive ventilation (NIV) lowers the risk of intubation and death for subjects with respiratory failure secondary to COPD exacerbations, but whether administration of NIV by a specialized, dedicated team improves its efficiency remains uncertain. Our aim was to test whether a dedicated team of respiratory therapists applying all acute NIV treatments would reduce the risk of intubation or death for subjects with COPD admitted for respiratory failure. METHODS: We carried out a retrospective study comparing subjects with COPD admitted to the ICU before (2001-2003) and after (2010-2012) the creation of a dedicated NIV team in a regional acute care hospital. The primary outcome was the risk of intubation or death. The secondary outcomes were the individual components of the primary outcome and ICU/hospital stay. RESULTS: A total of 126 subjects were included: 53 in the first cohort and 73 in the second. There was no significant difference in the demographic characteristics and severity of respiratory failure. Fifteen subjects (28.3%) died or had to undergo tracheal intubation in the first cohort, and only 10 subjects (13.7%) in the second cohort (odds ratio 0.40, 95% CI 0.16-0.99, P = .04). In-hospital mortality (15.1% vs 4.1%, P = .03) and median stay (ICU: 3.1 vs 1.9 d, P = .04; hospital: 11.5 vs 9.6 d, P = .04) were significantly lower in the second cohort, and a trend for a lower intubation risk was observed (20.8% vs 11% P = .13). CONCLUSIONS: The delivery of NIV by a dedicated team was associated with a lower risk of death or intubation in subjects with respiratory failure secondary to COPD exacerbations. Therefore, the implementation of a team administering all NIV treatments on a 24-h basis should be considered in institutions admitting subjects with COPD exacerbations.